NCT06651034

Efficacy of Intralesional Platelet Rich Plasma in Patients of De Quervain's Tenosynovitis

Completed NA Last updated 21 October 2024

What this trial tests

NA trial testing Platelet Rich Plasma in De Quervain Tenosynovitis in 67 participants. Completed in 30 October 2022.

Timeline

1 September 2021

Primary endpoint
30 October 2022

30 October 2022

Quick facts

Lead sponsor	Muhammad Aamir Latif
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	67
Start date	1 September 2021
Primary completion	30 October 2022
Estimated completion	30 October 2022
Sites	1 location across Pakistan

Drugs / interventions tested

• Platelet Rich Plasma — full drug profile →

Conditions studied

• De Quervain Tenosynovitis — all drugs for De Quervain Tenosynovitis →

Sponsor

Muhammad Aamir Latif — full company profile →

Who can join

Adults 18 to 60, any sex, with De Quervain Tenosynovitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

De Quervain's tenosynovitis (DQT) was originally identified by Swiss surgeon Fritz de Quervain in 1895. It is a condition involving the entrapment of tendons within the first dorsal compartment of the wrist. In DQT, the sheaths surrounding the abductor pollicis longus (APL) and extensor pollicis brevis tendons thicken as they pass through a fibro-osseous tunnel near the radial styloid of the distal wrist. This thickening leads to pain, which worsens with thumb movements and radial or ulnar deviation of the wrist. Traditional treatment methods, such as corticosteroid injections and physical therapy, often provide only temporary relief and may not address the underlying inflammation effectively. Intralesional platelet rich plasma (PRP) therapy has emerged as a promising alternative, utilizing the patient's own growth factors and cytokines to promote healing and reduce inflammation. By investigating the efficacy of intralesional PRP in patients with DQT, this research aims to provide evidence for a minimally invasive treatment option that could enhance recovery times, reduce pain, and improve functional outcomes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Efficacy of Intralesional Platelet-Rich Plasma in Patients With de Quervain's Tenosynovitis.
   Iqbal MT, Awais MZ, Mussab RM. · · 2025 · PMID 40151706 · DOI 10.7759/cureus.79617